비알코올성 지방간염 바이오마커 시장 규모, 점유율, 성장 분석 : 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 12.59 Billion by 2033, growing at a CAGR of 28.7% during the forecast period (2026-2033).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing robust growth, driven by the rising prevalence of NASH linked to obesity and metabolic disorders. As the disease incidence escalates, there is an increasing demand for precise biomarkers essential for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are vital for identifying individuals at risk, distinguishing NASH from other liver diseases, and assessing severity levels. The market is also benefiting from advancements in research and development, particularly the identification of novel biomarkers and the creation of non-invasive diagnostic tools. This burgeoning market is well-positioned to meet the critical need for effective diagnostic and monitoring solutions, presenting substantial opportunities for innovative biomarker-based interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-alcoholic Steatohepatitis Biomarkers Market Segments Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A significant driver of the global Non-alcoholic Steatohepatitis (NASH) biomarkers market is the increasing global prevalence of this liver condition, characterized by fat accumulation in the liver leading to inflammation and damage. Factors such as rising obesity rates, sedentary lifestyles, and poor dietary choices are contributing to the heightened occurrence of NASH. Consequently, there is a growing necessity for reliable biomarkers that can effectively diagnose the disease, monitor its progression, and evaluate treatment responses. The demand for NASH biomarkers continues to surge, fueled by heightened awareness of the condition and the imperative for enhanced diagnostic solutions.

Restraints in the Global Non-alcoholic Steatohepatitis Biomarkers Market

One of the major challenges facing the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers alongside regulatory hurdles. The intricate processes involved in the development and validation of these biomarkers for diagnosing and monitoring NASH contribute to the difficulty in achieving broad acceptance. A lack of agreement on the selection and application of biomarkers further complicates matters, making it hard for them to gain traction in clinical settings. Moreover, the stringent validation requirements set by regulatory bodies can be both time-consuming and expensive for companies. Addressing these issues through further research, standardization, and improved regulatory guidance is essential for realizing the full potential of NASH biomarkers in enhancing patient outcomes.

Market Trends of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A prominent trend in the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the escalating emphasis on non-invasive diagnostic methodologies. Given the intricate nature and progressive characteristics of NASH, timely and precise diagnosis is essential for effective disease management and treatment. Non-invasive biomarkers, including blood-based tests and advanced imaging techniques, are gaining popularity due to their advantages over traditional invasive liver biopsies, such as minimizing patient discomfort, lowering costs, and facilitating broader accessibility. This shift towards reliable and convenient diagnostic tools not only promises to improve patient outcomes but also enhances the efficiency of clinical trials, propelling the growth of the NASH biomarkers market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2026-2033)

• Market Overview
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Research Institutes and Academics
• Diagnostic Centres
• Pharmaceutical Companies and CROs
• Hospitals and Clinics
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2026-2033)

• North America (Type, End User)
  • US
  • Canada
• Europe (Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Genfit SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prometheus Laboratories Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perspectum Ltd (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Medicine Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopredictive (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations